New Tech Challenges Stage 4
04/08/21 • 28 min
Dr. Arya Amini, faculty radiation oncologist at City of Hope Cancer Center, joins Sean to discuss the promise and complexity of envelope-pushing therapies and current state of clinical research. Dr. Amini's fascination with cancer took hold in high school, continued through medical school, and ultimately has brought him to the field of radiation oncology – allowing him to focus on both patients and research. Hear how the industry has shifted from IMRT to SBRT and now a focus on both local and systemic therapies to treat metastatic disease. This forward-thinking conversation covers a lot of ground and you don't want to miss it.
Speakers:
Arya Amini, M.D. - Assistant Clinical Professor and Chief of Thoracic Radiotherapy, Department of Radiation Oncology for City of Hope Comprehensive Cancer Center
Sean Shirvani, M.D. - Chief Medical Officer, RefleXion
For more information, please visit https://reflexion.com
Dr. Arya Amini, faculty radiation oncologist at City of Hope Cancer Center, joins Sean to discuss the promise and complexity of envelope-pushing therapies and current state of clinical research. Dr. Amini's fascination with cancer took hold in high school, continued through medical school, and ultimately has brought him to the field of radiation oncology – allowing him to focus on both patients and research. Hear how the industry has shifted from IMRT to SBRT and now a focus on both local and systemic therapies to treat metastatic disease. This forward-thinking conversation covers a lot of ground and you don't want to miss it.
Speakers:
Arya Amini, M.D. - Assistant Clinical Professor and Chief of Thoracic Radiotherapy, Department of Radiation Oncology for City of Hope Comprehensive Cancer Center
Sean Shirvani, M.D. - Chief Medical Officer, RefleXion
For more information, please visit https://reflexion.com
Previous Episode
Intersect - Metastatic Disease Pt. 3
Sean is joined by Dr. George Simon, Executive Director of Moffitt Cancer Center-AdventHealth joint Clinical Research Unit, to identify key crossroads in the treatment landscape for metastatic cancer patients. If the distinctions among systemic, local, and immunotherapies are a bit baffling to you they won't be for long. Dr. Simon details these and other approaches such as checkpoint inhibitors, available in the just the last five years or so. The pace of change is exhilarating for physicians and patients. Though there is still much to learn, there is also much to celebrate.
Speakers:
George Simon, M.D. - Executive Medical Director and Department Chair, Moffitt Cancer Center-AdventHealth joint Clinical Research Unit
Sean Shirvani, M.D. - Chief Medical Officer, RefleXion
For more information, please visit https://reflexion.com
Next Episode
One-Two Punch to Cancer
Thorsten Melcher Ph.D., CBO at RefleXion, and Dr. Giovanni Selvaggi, CEO and CMO at Xcovery, discuss advances in two key areas that could mean a longer life for more Stage 4 patients. The watchwords are customization and personalization. The finding that the customized pairing of two therapies, used in combination, versus in a sequence, creates a synergistic effect, is coupled with the realization every patient's cancer is personalized to their unique system. Developing a plan that includes a patient assessment, multiple treatment options, and how best to combine them, is a promising new direction.
Speakers:
Thorsten Melcher Ph.D. - CBO, RefleXion
Giovanni Selvaggi, M.D. - CEO & CMO, Xcovery
For more information, please visit https://reflexion.com
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/reflexion-podcast-329774/new-tech-challenges-stage-4-48122298"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to new tech challenges stage 4 on goodpods" style="width: 225px" /> </a>
Copy